Back to News
Market Impact: 0.45
Pharvaris Reports Positive Phase 3 CHAPTER-3 Results For Deucrictibant XR In HAE Prophylaxis
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Pharvaris announced positive topline results from its pivotal Phase 3 CHAPTER-3 trial of deucrictibant extended-release tablets for prevention of hereditary angioedema attacks. The positive late-stage clinical readout materially supports the drug's development and potential regulatory path, likely benefiting Pharvaris shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
PHVS0.85
More News
- Pharvaris reports positive phase 3 results for HAE drug
- Pharvaris stock surges 27% on positive trial data
- Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
- Nvidia Earnings Blow Everyone Away
- China's EV makers shift gears to focus on humanoids as car market slows
- Chipotle's new restaurant in a hip Seoul neighborhood tests its Asian expansion strategy